TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33876241

Group type: EXPERIMENTAL
Intervention: X-ray-guided interventional procedures (EVAR procedures)
Number of subjects: 70
Study: 32967939

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus radiotherapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 67
Study: 36102414

Group type: EXPERIMENTAL
Intervention: 5 Hz frequency
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 250 Hz frequency
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 2 KHz frequency
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sinusoidal waveform
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Square waveform
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 250 μs‐pulsed waveform
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Conventional electrode configuration
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Concentric electrode configuration
Number of subjects: 19
Study: 34992749

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (ImRs)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual Care and Treatment Advice (UC+TA)
Number of subjects: 90
Study: 35807911

Group type: EXPERIMENTAL
Intervention: Healthy cooking training only
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Subsidization with healthy cooking training
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control
Number of subjects: 340
Study: 32803439

Group type: EXPERIMENTAL
Intervention: Preoperative submucosal corticosteroid injection (n = 16), 8 mg/2 ml dexamethasone 21‐phosphate
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Postoperative therapeutic elastic bandage application (n = 19), Kinesio tapes applied to operated sites
Number of subjects: 52

Group type: COMPARATOR
Intervention: Postoperative non‐steroid anti‐inflammatory drug therapy (n = 17), 25 mg dexketoprofen trometamol
Number of subjects: 52
Study: 34718947

Group type: EXPERIMENTAL
Intervention: Culturally adapted GenerationPMTO (CAPAS-Youth)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 71
Study: 34872117

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 54
Study: 32528568

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily (30 mg for creatinine clearance 15-50 mL/min, weight ≤ 60 kg, and/or concomitant use of P-glycoprotein inhibitor)
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Enoxaparin-warfarin
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2199
Study: 35694711

Group type: EXPERIMENTAL
Intervention: Herbal moxibustion on the navel combined with mind-regulating acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Herbal moxibustion on the navel
Number of subjects: 60
Study: 36041346

Group type: EXPERIMENTAL
Intervention: Securement Bundle 2 (two sterile tape strips over PIVC hub plus Standard care)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Securement Bundle 1 (two sterile tape strips over PIVC hub plus Standard care)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard care (bordered polyurethane dressing plus non-sterile tape over extension tubing)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Incidence rate ratio for PIVC failure/1000 catheter days for Bundle 1 compared to Standard care
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Incidence rate ratio for PIVC failure/1000 catheter days for Bundle 2 compared to Standard care
Number of subjects: 109
Study: 33586583

Group type: EXPERIMENTAL
Intervention: Curcuma longa L. (500 mg/day with piperine 5 mg)
Number of subjects: 71
Study: 33196676

Group type: EXPERIMENTAL
Intervention: Contact-guided replica-exchange molecular dynamics (REMD) with approximately 75% true-positive contacts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration of varying numbers of randomly selected native and non-native contacts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contact-guided REMD
Number of subjects: 0
Study: 35184724

Group type: EXPERIMENTAL
Intervention: No sentinel lymph node biopsy (no-SLNB)
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 1734
Study: 33472757

Group type: EXPERIMENTAL
Intervention: Hand massage
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no hand massage)
Number of subjects: 97
Study: 32605501

Group type: EXPERIMENTAL
Intervention: 1% 5‐fluorouracil cream
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5% 5‐fluorouracil cream
Number of subjects: 72

Group type: COMPARATOR
Intervention: 90% trichloroacetic acid
Number of subjects: 72
Study: 34217258

Group type: EXPERIMENTAL
Intervention: Information leaflet on the benefits and harms of mammography screening
Number of subjects: 11119

Group type: COMPARATOR
Intervention: Usual invitation letter
Number of subjects: 11119
Study: 35802150

Group type: EXPERIMENTAL
Intervention: RIRS without UAS (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 11Fr/13Fr Boston scientific Navigator™ UAS (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 11Fr/13Fr dual lumen ClearPetra™ UAS (Group 3)
Number of subjects: 60
Study: 34582454

Group type: EXPERIMENTAL
Intervention: Increase in caregivers' gender-equitable attitudes
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Older girls
Number of subjects: 732
Study: 34996820

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac, 10 mg, three times daily for a maximum of 5 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard medical treatment (Control group)
Number of subjects: 56
Study: 34878869

Group type: EXPERIMENTAL
Intervention: Cash plus intervention
Number of subjects: 904
Study: 35416167

Group type: EXPERIMENTAL
Intervention: 3D model‐assisted surgery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 32
Study: 33781284

Group type: EXPERIMENTAL
Intervention: Theory‐informed in‐practice training session plus individualised audit and feedback
Number of subjects: 228

Group type: COMPARATOR
Intervention: Audit and feedback alone
Number of subjects: 228
Study: 33510184

Group type: EXPERIMENTAL
Intervention: Elevated triglycerides and pro-inflammatory markers (TNF? and IL6)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: High levels of triglycerides, TNF?, and IL6 coupled with low levels of HDL-C
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Poorly controlled diabetes (HbA1c > 6.5)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 215
Study: 35786347

Group type: EXPERIMENTAL
Intervention: Selective Laser Sintering (SLS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional Lost-Wax Casting
Number of subjects: 18
Study: 34103623

Group type: EXPERIMENTAL
Intervention: Flywheel exercise with three different moments of inertia
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Flywheel exercise (general)
Number of subjects: 21
Study: 36318322

Group type: EXPERIMENTAL
Intervention: Ultra-congruent (UC) device
Number of subjects: 185

Group type: COMPARATOR
Intervention: Condylar-stabilizing (CS) device
Number of subjects: 185

Group type: COMPARATOR
Intervention: Posterior-stabilized (PS) device
Number of subjects: 185
Study: 33555114

Group type: EXPERIMENTAL
Intervention: Atrial Flow Regulator (AFR) device
Number of subjects: 53
Study: 32178430

Group type: EXPERIMENTAL
Intervention: Agility training (supervised, group-based, twice a week for one year)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 85
Study: 32737893

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1000 mg intravenous)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 35820112

Group type: EXPERIMENTAL
Intervention: Intensive multimodality therapy including four cycles of chemotherapy followed by involved field radiation therapy (45 Gy) for stage II-III patients.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intensive multimodality therapy including four cycles of chemotherapy followed by involved field radiation therapy (45 Gy) for stage IVa patients.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intensive multimodality therapy including four cycles of chemotherapy and one cycle of high-dose carboplatin, thiotepa, and etoposide with autologous hematopoietic stem-cell support for stage IVb patients.
Number of subjects: 57
Study: 33369684

Group type: EXPERIMENTAL
Intervention: Virtual reality-based neck-specific sensorimotor training
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation programme)
Number of subjects: 51

Group type: COMPARATOR
Intervention: General sensorimotor training (group therapy)
Number of subjects: 51
Study: 34542910

Group type: EXPERIMENTAL
Intervention: Self-administered anonymous questionnaire assessing misconceptions about oral radiology and medicine
Number of subjects: 1380
Study: 32827410

Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercises (DBE) for 5 minutes every day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no DBE)
Number of subjects: 60
Study: 34119566

Group type: EXPERIMENTAL
Intervention: Intrathecal Clonidine Group (ITCG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous Clonidine Group (IVCG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study: 33015926

Group type: EXPERIMENTAL
Intervention: Nutritional support team (NST) intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: No nutritional support team (NST) intervention (Control)
Number of subjects: 61
Study: 34165612

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) group practiced guided mindfulness meditation for a minimum of 10 minutes each day for 10 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist Control (WC) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) group
Number of subjects: 0
Study: 34732775

Group type: EXPERIMENTAL
Intervention: 20 mg hydrocortisone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34244182

Group type: EXPERIMENTAL
Intervention: Mindful gratitude journaling
Number of subjects: 92

Group type: COMPARATOR
Intervention: Routine journaling (Control)
Number of subjects: 92
Study: 36385638

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention for seniors (MBIS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for anxiety
Number of subjects: 24

Group type: COMPARATOR
Intervention: Care-as-usual control group
Number of subjects: 24
Study: 32641330

Group type: EXPERIMENTAL
Intervention: Perioperative recorded music interventions in addition to standard care
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 170
Study: 33535786

Group type: EXPERIMENTAL
Intervention: Genetically predicted years of education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waist-hip ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education, body mass index, and smoking
Number of subjects: 0
Study: 34708513

Group type: EXPERIMENTAL
Intervention: Experimental diet (Ex-diet)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control diet (C-diet)
Number of subjects: 115
Study: 32269052

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 28
Study: 35120572

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Double-blind placebo (DBP)
Number of subjects: 33
Study: 33058795

Group type: EXPERIMENTAL
Intervention: Cefiderocol (2 g every 8 hours for 7–14 days)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Best available therapy (pre-specified by the investigator, maximum of three drugs for 7–14 days)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 152

Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 152
Study: 32701597

Group type: EXPERIMENTAL
Intervention: Sertraline (SSRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35493817

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 20 min, 15 sessions over 3 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 24
Study: 32221151

Group type: EXPERIMENTAL
Intervention: Phenylephrine and ketorolac (PE/K) 1.0%/0.3%
Number of subjects: 72

Group type: COMPARATOR
Intervention: Phenylephrine (PE) 1.0%
Number of subjects: 72
Study: 33527476

Group type: EXPERIMENTAL
Intervention: Self-kindness exercises
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Mindfulness exercises
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Common humanity exercises
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study: 36060713

Group type: EXPERIMENTAL
Intervention: Online mindfulness program (group M)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo sessions (group C)
Number of subjects: 90
Study: 32075010

Group type: EXPERIMENTAL
Intervention: EX-LC (structured supervised exercise program + low-carbohydrate meals)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ketogenic state (βHB ≥0.3 mmol/L)
Number of subjects: 64

Group type: COMPARATOR
Intervention: EX-CO (structured supervised exercise program + standard dietary advice)
Number of subjects: 64
Study: 36120766

Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Muscle energy technique (MET)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (home exercise program)
Number of subjects: 45
Study: 32940893

Group type: EXPERIMENTAL
Intervention: Sodium Tanshinone IIA Sulfonate (STS), n = 192
Number of subjects: 372

Group type: COMPARATOR
Intervention: Saline (Control), n = 180
Number of subjects: 372
Study: 33327227

Group type: EXPERIMENTAL
Intervention: Formulated food (n = 80)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo group (n = 40)
Number of subjects: 120
Study: 34802052

Group type: EXPERIMENTAL
Intervention: Sub-brow technique
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lid crease technique
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Direct mini-incision technique
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 47
Study: 34824982

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy (ICBT) including psychoeducation, cognitive restructuring, attentional training, and exposure.
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Hypothesized change mechanisms include the increase of knowledge about SAD, the decrease of dysfunctional cognitions, the decrease of self‐focused attention, and the decrease of avoidance and safety behaviors.
Number of subjects: 464
Study: 36409435

Group type: EXPERIMENTAL
Intervention: TAK-931 80 mg tablet
Number of subjects: 20

Group type: COMPARATOR
Intervention: TAK-931 80 mg PIC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TAK-931 50 mg PIC QD
Number of subjects: 20
Study: 32633151

Group type: EXPERIMENTAL
Intervention: Humor correction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-humor correction
Number of subjects: 0
Study: 32091032

Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy (ILIT) with pollen extracts, 3 intralymphatic inguinal injections before the first pollen season.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy (ILIT) with pollen extracts.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment (control group).
Number of subjects: 18
Study: 35598154

Group type: EXPERIMENTAL
Intervention: Splanchnic ablation for volume management (SAVM)
Number of subjects: 18
Study: 33734539

Group type: EXPERIMENTAL
Intervention: Brief video-based intervention
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Written vignette intervention
Number of subjects: 172

Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 172
Study: 35807924

Group type: EXPERIMENTAL
Intervention: Low avocado allotment (3 avocados)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High avocado allotment (14 avocados)
Number of subjects: 0
Study: 34296837

Group type: EXPERIMENTAL
Intervention: High-velocity low-amplitude (HVLA) thrust manipulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 10
Study: 32966320

Group type: EXPERIMENTAL
Intervention: Previous training session
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Current training session
Number of subjects: 341

Group type: COMPARATOR
Intervention: Participants with less than 1,000 flight hours
Number of subjects: 341

Group type: COMPARATOR
Intervention: Participants with more than 1,000 flight hours
Number of subjects: 341
Study: 34694872

Group type: EXPERIMENTAL
Intervention: Telacebec (Q203) 10 to 800 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Telacebec (Q203) 10 to 800 mg (fed condition)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 32721815

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 100
Study: 35401774

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) + physiotherapy treatment (PT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Physiotherapy treatment (PT)
Number of subjects: 76
Study: 34284834

Group type: EXPERIMENTAL
Intervention: Childhood exposed group
Number of subjects: 9055

Group type: EXPERIMENTAL
Intervention: Adolescence exposed group
Number of subjects: 9055

Group type: COMPARATOR
Intervention: Fetal/infant exposed group
Number of subjects: 9055

Group type: COMPARATOR
Intervention: Unexposed group
Number of subjects: 9055

Group type: COMPARATOR
Intervention: Males in all famine exposed groups
Number of subjects: 9055
Study: 32213042

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy for 3 days or less
Number of subjects: 296

Group type: COMPARATOR
Intervention: Antimicrobial therapy for 4 days or more
Number of subjects: 296
Study: 36067369

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Number of subjects: 11486

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol) in men with baseline 25‐hydroxyvitamin D <20 ng/mL
Number of subjects: 11486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11486
Study: 34741513

Group type: EXPERIMENTAL
Intervention: Chatbot recruitment
Number of subjects: 935

Group type: COMPARATOR
Intervention: Telephone-based recruitment
Number of subjects: 935
Study: 34966900

Group type: EXPERIMENTAL
Intervention: Abatacept (125 mg subcutaneous every week)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Abatacept (during open-label extension)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (transitioned to abatacept during open-label extension)
Number of subjects: 88
Study: 35789818

Group type: EXPERIMENTAL
Intervention: Continuous fascia iliaca compartment block (CFICB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA)
Number of subjects: 60
Study: 35792520

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inotrope therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levosimendan
Number of subjects: 0
Study: 33452192

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 138

Group type: COMPARATOR
Intervention: Weekly paclitaxel (chemotherapy)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Olaparib and cediranib
Number of subjects: 138
Study: 34237265

Group type: COMPARATOR
Intervention: Normal blood pressure (sBP <120 mm Hg and dBP <80 mm Hg)
Number of subjects: 21069

Group type: EXPERIMENTAL
Intervention: Severe stage 2 hypertension (sBP ≥160 mm Hg or dBP ≥110 mm Hg)
Number of subjects: 21069

Group type: COMPARATOR
Intervention: Elevated blood pressure (sBP 120–129 mm Hg and dBP <80 mm Hg)
Number of subjects: 21069

Group type: COMPARATOR
Intervention: Stage 1 hypertension (sBP 130–139 mm Hg or dBP 80–89 mm Hg, or both)
Number of subjects: 21069

Group type: COMPARATOR
Intervention: Non‐severe stage 2 hypertension (sBP 140–159 mm Hg or dBP 90–109 mm Hg, or both)
Number of subjects: 21069
Study: 32398341

Group type: EXPERIMENTAL
Intervention: 7 days antibiotic treatment
Number of subjects: 3626

Group type: COMPARATOR
Intervention: 14 days antibiotic treatment
Number of subjects: 3626
Study: 35264365

Group type: EXPERIMENTAL
Intervention: Left atrial epicardial conduction time (LAECT) measured in patients with conduction block across the roof and trigone lesion.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: LAECT
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: LAECT, previously failed catheter ablation, and BMI
Number of subjects: 121
Study: 32910135

Group type: EXPERIMENTAL
Intervention: Faricimab (dosing every four months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faricimab (dosing quarterly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 0
Study: 36493791

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks
Number of subjects: 852

Group type: COMPARATOR
Intervention: Placebo every 2 weeks
Number of subjects: 852

Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks (after switch from placebo at week 16)
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Overall treatment-emergent adverse events
Number of subjects: 852
Study: 34419529

Group type: EXPERIMENTAL
Intervention: 6-month home-based mobile CR programme with telemonitoring and coaching based on motivational interviewing (n=79)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (n=100)
Number of subjects: 179